



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

15 January 2015
EMA/789664/2014

International Generic Drug Regulators Programme (IGDRP) Information Sharing Pilot

Information package on Participation in the Information Sharing Pilot for the Evaluation of Generic Drug Applications Involving the Centralised Procedure of the European Union

The International Generic Drug Regulators Pilot (IGDRP)¹ was launched in April 2012 in the face of mounting pressures that confront generic drug review programs worldwide and a willingness on the part of regulatory agencies to pursue collaboration and convergence in order to help mitigate these pressures. Broadly speaking, this would be realized through:

- increasing the efficiency of review procedures;
- strengthening the regulatory review process and human resource capacity;
- applying an appropriate level of global regulatory oversight through information exchange and coordination, while reducing unnecessary regulatory burden; and
- promoting the adoption of modern science and risk based approaches on the part of both industry and agencies.

Information sharing mechanisms and work-sharing models offer important means of achieving these objectives. One of the most significant developments in this regard involves the piloting of the European Union's Decentralised Procedure (DCP) as a model for the sharing of information with IGDRP competent authorities external to the EU during the scientific assessment phases of the DCP.

However, the opportunity to extend the pilot to applications for generic products submitted through the centralised procedure has been recognised. This information package provides information on how to apply for participation in the Information Sharing Pilot for the Evaluation of Generic Drug Applications Involving the Centralised Procedure (CP) of the European Union.

A generic drug applicant wishing to market the same product in the EU through the CP and in other jurisdictions that form part of IGDRP are invited to participate in this pilot provided that the criteria for eligibility listed below are met. This would include the requirement to file marketing applications in a synchronized manner in at least one of the IGDRP participating jurisdictions. A list of regulatory

¹ World Health Organization (WHO) Drug Information Vol. 28 No. 1, 2014
(www.who.int/medicines/publications/druginformation/DI_28-1_Regulatory-Harmonization.pdf?ua=1)



agencies that have expressed an interest to participate in the first round of the pilot is provided in Appendix 1. Additional agencies may choose to participate in subsequent stages of this pilot.

Under the arrangements established for the pilot, the assessment reports generated as part of the CP would be shared in real time with collaborating IGDRP agencies outside the EU, as illustrated in the schematic in Appendix 2.

Participation in the pilot would offer applicants the potential to obtain market authorization in chosen markets as part of a coordinated process. Experience gained by industry and regulatory agencies would help to refine the process and inform other information and work sharing models currently under consideration by regulatory agencies. The objective of the pilot is to provide for a more efficient and consistent review process while at the same time reducing regulatory burden and facilitating the similar timing of market authorizations across jurisdictions.

The applicant is required to provide consent to share the CP assessment reports with the non-EU agencies proposed in the EOI (see EOI Request form, Appendix 3). In case an Active Substance Master File (ASMF) is used in the application, consent from the ASMF holder to share the assessment report on the restricted part of the ASMF should also be provided (appendix 4). In order to further promote the value and impact of the pilot, interested applicants are allowed to provide consent for the sharing of CP assessment reports with other regulatory agencies that form part of IGDRP or may be of interest from a marketing perspective (see EOI Request form, Appendix 3).

Expressions of Interest related to the pilot should be forwarded to the contact points for candidate agencies selected by the applicant (see Appendix 1) and the EMA (IGDRPpilot@ema.europa.eu) at least 8 weeks prior to the intended submission of the application using the EOI form, together with a Summary of Quality Differences (appendix 5). Applications to this pilot are requested by 31 March, 2015.

Criteria for Eligibility for the Pilot

In order to qualify for consideration in the pilot, interested applicants must comply with the following criteria:

- Synchronized filing of generic drug applications for the same product in at least one of the IGDRP participating jurisdictions selected for the pilot. Synchronized filing means the applications are submitted at times defined by participating non-EU agencies in relation to the time of filing of the CP application. The timing will be made available by the IGDRP participating jurisdictions and will be defined in a manner that best aligns the review processes and the flow of information. This may be simultaneous or sequential, depending on the agency.
- Minor differences in products from the product that is intended to be authorised in the EU may be considered acceptable provided these differences are not expected to impact on the safety, efficacy or quality of the product and ensure a similarity the products/dossiers under assessment (e.g., differences in container closure system formats). Non-EU regulatory agencies identified for collaboration in the pilot will confirm the acceptability of any such differences upon review of information submitted with the EOI, including the completed *Summary of Quality Differences* (see below).
- Complete applications, compliant with respective regulatory requirements, will be filed with the jurisdictions participating in the exercise.
- Original generic drug applications for the following pharmaceutical (dosage) forms:
 - immediate-release, solid oral

- solutions (e.g., oral, injectable).
- When in-vitro or in-vivo comparative studies against a reference product are warranted, comparative studies should be against the reference product marketed in the jurisdiction of the non-EU regulatory agency participating in the pilot, or against another suitable reference product with the condition that the non-EU agency's requirements for the use of a foreign-sourced reference product are met.
- A completed Summary of Quality Differences form is submitted noting the differences, if any, between the products filed with the EU CP and the non-EU agency (Appendix 5).
- Consent is provided granting permission for the sharing of CP assessment reports with non-EU agencies involved in the pilot (Appendix 3 and 4).
- Practical knowledge on how to apply and run a CP is deemed as a prerequisite.


A verification assessment will be undertaken by non-EU agencies to determine whether the product being evaluated meets eligibility criteria.

Appendix 1: List of Regulatory Agencies in participating in the Information Sharing Pilot

Jurisdiction	Regulatory Agency	Contact information
Australia	Therapeutic Goods Administration (TGA)	PCSinbox@tga.gov.au
Canada	Health Canada	TPD-DPT.international@hc-sc.gc.ca
Chinese Taipei	Taiwan Food and Drug Administration (TFDA)	lin.bond@fda.gov.tw
Switzerland	Swissmedic - Swiss Agency for Therapeutic Products	Networking@swissmedic.ch

Appendix 2: Schematic of how the CP pilot would operate

Participation to the Information Sharing Pilot involving the CP will involve a parallel review process, with non-EU agencies continuing to conduct separate but synchronized receipt, validation/screening, assessment and market authorization (or refusal). EMA assessment reports will be shared once adopted by the EMA Committee for Human Medicinal Products (CHMP).



- *Option 1) Procedure ends at D120 → Sharing of D120 AR
- ** Option 2) Procedure ends at D180 → Sharing of D120, and D180 AR
- *** Option 3) Procedure ends at D210 → Sharing of D120, D180 and D210 AR

AR: Assessment Report
 LoQ: List of Questions
 LoOI: List of Outstanding Issues

Further Details on the centralised procedure for applications of generic medicinal product are available at the EMA website, "Human Regulatory", under the Pre-authorisation guidance for generic/hybrid applications.

(http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000033.jsp&mid=WC0b01ac0580027091).

Appendix 3: Expression of Interest (EOI) Request to Participate to the Information Sharing Pilot for the Evaluation of Generic Drug Applications involving the Centralised Procedure of the European Union

Product Information			
Product Name (should be same as on product label):			
Active Pharmaceutical Ingredient:			
Pharmaceutical Form	Route	Strength	Conditions of Use
Applicant Information			
Name (Full legal name):			
Address:			
Contact Person:			
Tel:	Fax:	Email:	
Application/submission filing information			
Intended filing date:			
CP-Number (if already known):			
Non-EU agencies proposed for this pilot: <ul style="list-style-type: none"> <input type="checkbox"/> Australia (Therapeutic Goods Administration (TGA)) <input type="checkbox"/> Canada (Health Canada) <input type="checkbox"/> Chinese Taipei (Taiwan Food and Drug Administration (TFDA)) <input type="checkbox"/> Switzerland (Swissmedic, Swiss Agency for Therapeutic Products) 			
Confirmation of Meeting Eligibility Criteria for Pilot			
This marketing application complies with all of the eligibility criteria listed in the Expression of Interest Notice including the following:			
Original generic drug application for the following pharmaceutical (dosage) forms: <ul style="list-style-type: none"> <input type="checkbox"/> immediate-release, solid oral <input type="checkbox"/> solutions (e.g., oral, injectable) 			
<input type="checkbox"/> When in-vitro or in-vivo comparative studies against a reference product are warranted, comparative studies comply with the requirements of the non-EU agencies proposed in this EOI request, as substantiated by evidence appended to the completed EOI Request.			
<input type="checkbox"/> A completed Summary of Quality Differences form is included as part of this EOI Request.			
Consent to share regulatory information			
The undersigned hereby acknowledges and gives consent to the sharing of CP assessment reports with the IGDRP agencies proposed in this EOI Request.			
If an Active Substance Master File (ASMF) is used with the application, please add consent from the ASMF holder to share the assessment report on the restricted part of the ASMF with the IGDRP agencies proposed in this EOI request. In case the ASMF holder consent is not provided, the assessment report on the restricted part of the ASMF will not be shared.			
In addition, the undersigned hereby acknowledges and gives consent to the sharing of the same information :			
<input type="checkbox"/> with all IGDRP agencies*, or			
<input type="checkbox"/> with the following agencies: _____			
Name of Authorized Signing Official: _____			
Title, Company: _____			
Signature **: _____			

Date: _____

* Agencies from the following jurisdictions form part of IGDRP: Australia, Brazil, Canada, China, Chinese Taipei, the European Union, the Republic of Korea, Japan, Mexico, New Zealand, Russia, Singapore, South Africa, Switzerland and the United States as well as the World Health Organization.

**Signatures (including digital/electronic versions, where permitted) must comply with the legal requirements of the jurisdiction(s) in which the EOI is being submitted.

Appendix 4: Consent Form to share regulatory information on the restricted part of the Active Substance Master File (ASMF) in the Information Sharing Pilot for the Evaluation of Generic Drug Applications involving the Centralised Procedure of the European Union

Consent to share regulatory information on the restricted part of the ASMF

The undersigned hereby acknowledges and gives consent to the sharing of CP assessment reports on the restricted part of the ASMF with the IGDRP agencies proposed in this EOI Request.

In addition, the undersigned hereby acknowledges and gives consent to the sharing of the same information :

- with all IGDRP agencies* , or
 with the following agencies:_____

Name of Authorized Signing Official: _____

Title, Company: _____

Signature **: _____

Date: _____

* Agencies from the following jurisdictions form part of IGDRP: Australia, Brazil, Canada, China, Chinese Taipei, the European Union, the Republic of Korea, Japan, Mexico, New Zealand, Russia, Singapore, South Africa, Switzerland and the United States as well as the World Health Organization.

**Signatures (including digital/electronic versions, where permitted) must comply with the legal requirements of the jurisdiction(s) in which the EOI is being submitted.

Appendix 5: Summary of Quality Differences

This form must be completed and submitted to each Non-EU agency proposed in the EOI Request

Summary of Quality Differences			
Modules and numbering reflect the ICH Common Technical Document.			
Modules where there are no differences between the products filed with the EU CP/DCP (delete as appropriate) and the non-EU agency should be reported as “No differences”. Where minor differences exist for a listed module, a brief summary of the details should be described.			
Module	Details in application to be filed with the EU CP/DCP (delete as appropriate)	Details in application to be filed with the non-EU agency	Discussion of noted differences
3.2.S Drug Substance			
3.2.S.1 General Information			
3.2.S.2 Manufacture			
3.2.S.3 Characterisation			
3.2.S.4 Control of the Drug Substance			
3.2.S.5 Reference Standard or Materials			
3.2.S.6 Container Closure System			
3.2.S.7 Stability			
3.2.P Drug Product			
3.2.P.1 Description and Composition of the Drug Product			
3.2.P.2 Pharmaceutical Development			
3.2.P.3 Manufacture			
3.2.P.4 Control of Excipients			
3.2.P.5 Control of Drug Product			
3.2.P.6 Reference Standard or Materials			
3.2.P.7 Container Closure System			
3.2.P.8 Stability			